Why we need biomarkers
Reading Time: 3 minutes Yesterday’s announcement by the biotechnology company Trophos SA of the lack of effectiveness of their compound olesoxime adds to the long list of drugs that have failed to live up to their early promise in the lab. It’s a story that’s common across the world of neurodegenerative disease, including common conditions such as Parkinson’s disease…